All Stories

  1. Lipid nanoparticles for siRNA delivery in cancer treatment
  2. Self-assembled lipid–prodrug nanoparticles
  3. Cardiac tissue engineering for myocardial infarction treatment
  4. Hydrogels for brain repair: application to Parkinson’s disease
  5. Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering
  6. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system
  7. Special issue on the latest advances in regenerative medicine and cancer using drug delivery systems
  8. In vivo biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99 m: Comparison of administration routes in mice
  9. Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors: A comparative study
  10. Decoration of Squalenoyl‐Gemcitabine Nanoparticles with Squalenyl‐Hydroxybisphosphonate for the Treatment of Bone Tumors
  11. Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
  12. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment
  13. Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction
  14. Optimization of a GDNF production method based on Semliki Forest virus vector
  15. Special Issue “A perspective of drug delivery and translational research in Europe”
  16. Extracellular Vesicle-Based Therapeutics for Heart Repair
  17. SPION and doxorubicin-loaded polymeric nanocarriers for glioblastoma theranostics
  18. Morphology, gelation and cytotoxicity evaluation of D-α-Tocopheryl polyethylene glycol succinate (TPGS) – Tetronic mixed micelles
  19. Improving the genistein oral bioavailability via its formulation into the metal–organic framework MIL-100(Fe)
  20. Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms
  21. Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
  22. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice
  23. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy
  24. Nanomedicine and drug delivery systems in cancer and regenerative medicine
  25. Co-encapsulation of superparamagnetic nanoparticles and doxorubicin in PLGA nanocarriers: Development, characterization and in vitro antitumor efficacy in glioma cells
  26. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine
  27. Long-Term Engraftment of Human Cardiomyocytes Combined with Biodegradable Microparticles Induces Heart Repair
  28. Micro- and nanotechnology approaches to improve Parkinson's disease therapy
  29. Therapeutic Opportunities in Neuroblastoma Using Nanotechnology
  30. Advances in Parkinson’s Disease: 200 Years Later
  31. Biocompatible porous metal-organic framework nanoparticles for gentamicin vectorization
  32. NRG1 PLGA MP locally induce macrophage polarisation toward a regenerative phenotype in the heart after acute myocardial infarction
  33. Nanomedicines for Pediatric Cancers
  34. Oral nanoencapsulated ET causes regression of lung metastases in models of osteosarcoma
  35. Heart tissue repair and cardioprotection using drug delivery systems
  36. Visualization of hybrid gold-loaded polymeric nanoparticles in cells using SEM
  37. Special Issue: Pharmaceutics and Drug Delivery in Spain
  38. Breaching barriers in glioblastoma: Targeted drug delivery
  39. Breaching barriers in glioblastoma: novel treatment approaches
  40. Hydrogel based approaches for cardiac tissue engineering
  41. Cytokine-loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration
  42. Special issue on biomaterials for tissue engineering
  43. Effectiveness of nanoencapsulated methotrexate against osteosarcoma cells
  44. Transplantation of ADSC combined with neuregulin-microparticles promotes efficient cardiac repair
  45. The combination of DOX and ET is likely to be effective against osteosarcoma.
  46. Nanotechnology-based drug delivery systems for Alzheimer's disease management
  47. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys
  48. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein
  49. Clinical advances of nanocarrier-based cancer therapy and diagnostics
  50. Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion
  51. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation
  52. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease
  53. Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies
  54. Reformulating cyclosporine A (CsA): More than just a life cycle management strategy
  55. Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems
  56. A simple approach to obtain hybrid Au-loaded polymeric nanoparticles with a tunable metal load
  57. Lipid nanoparticles for osteosarocma therapy
  58. Tracking the in vivo release of bioactive NRG from PLGA and PEG–PLGA microparticles in infarcted hearts
  59. Lípidos nanoparticles for oral CyA administration
  60. Polymeric Electrospun Scaffolds: Neuregulin Encapsulation and Biocompatibility Studies in a Model of Myocardial Ischemia
  61. Heart regeneration after myocardial infarction using synthetic biomaterials
  62. A Zn azelate MOF: combining antibacterial effect
  63. Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
  64. Lipid nanoparticles protect from edelfosine toxicity in vivo
  65. Edelfosine Lipid Nanoparticles Overcome Multidrug Resistance in K-562 Leukemia Cells by a Caspase-Independent Mechanism
  66. Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
  67. In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
  68. Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy
  69. Cytotoxicity of nanoscaled metal–organic frameworks
  70. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration
  71. Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia
  72. Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
  73. Efficacy of edelfosine lipid nanoparticles in breast cancer cells
  74. Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia
  75. Injectable alginate hydrogel loaded with GDNF promotes functional recovery in a hemisection model of spinal cord injury
  76. A simple and robust high-performance liquid chromatography coupled to a diode-array detector method for the analysis of genistein in mouse tissues
  77. Adipose-derived stem cells combined with Neuregulin-1 delivery systems for heart tissue engineering
  78. Vascular endothelial growth factor‐loaded injectable hydrogel enhances plasticity in the injured spinal cord
  79. Biographies featuring the special issue editors Dr. M.N.V. Ravi Kumar, Dr. María J. Blanco-Prieto and D.N. Waterhouse
  80. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines
  81. Nanotheraputics
  82. Gentamicin-Loaded Nanoparticles Are Effective against Brucella melitensis
  83. Ultra high performance liquid chromatography–tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems
  84. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system
  85. Editorial
  86. PEGylated-PLGA microparticles containing VEGF for long term drug delivery
  87. Brain Drug Delivery Systems for Neurodegenerative Disorders
  88. Lipid nanoparticles for cancer therapy: state of the art and future prospects
  89. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin
  90. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles
  91. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
  92. Vascular Endothelial Growth Factor-Delivery Systems for Cardiac Repair: An Overview
  93. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma
  94. Development and validation of ultra high performance liquid chromatography–mass spectrometry method for LBH589 in mouse plasma and tissues
  95. Angiogenic therapy for cardiac repair based on protein delivery systems
  96. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease
  97. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections
  98. High Loading of Gentamicin in Bioadhesive PVM/MA Nanostructured Microparticles Using Compressed Carbon-Dioxide
  99. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia–reperfusion model
  100. Lipid raft-targeted therapy in multiple myeloma
  101. In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts
  102. Drug delivery systems for potential treatment of intracellular bacterial infections
  103. Production of highly pure human glycosylated GDNF in a mammalian cell line
  104. Comparative study of A HPLC–MS assay versus an UHPLC–MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems
  105. Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
  106. Antitumor Alkyl Ether Lipid Edelfosine: Tissue Distribution and Pharmacokinetic Behavior in Healthy and Tumor-Bearing Immunosuppressed Mice
  107. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres
  108. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization
  109. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor
  110. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections
  111. Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum‐Based Chemotherapy
  112. Poly(d,l-Lactide-Coglycolide) Particles Containing Gentamicin: Pharmacokinetics and Pharmacodynamics in Brucella melitensis- Infected Mice
  113. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson
  114. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  115. Nanocarriers with Gentamicin to Treat Intracellular Pathogens
  116. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin
  117. Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method
  118. Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin
  119. Polymeric Particulates to Improve Oral Bioavailability of Peptide Drugs
  120. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography–electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems
  121. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres
  122. High-performance liquid–chromatographic determination of rifampicin in plasma and tissues
  123. Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography
  124. Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies
  125. Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture
  126. Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters
  127. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  128. In vitro evaluation of gentamicin released from microparticles
  129. Optimization of topical cidofovir penetration using microparticles
  130. PLGA microparticles: possible vehicles for topical drug delivery
  131. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers
  132. In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres
  133. Importance of the test medium for the release kinetics of a somatostatin analogue from poly(?-lactide-co-glycolide) microspheres
  134. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides